Top Page
Plus Therapeutics
(NASDAQ:PSTV)
Plus Therapeutics (PSTV) vs. SPDR S&P 500 ETF (SPY)
Plus Therapeutics Business Overview & Revenue Model
Plus Therapeutics Earnings Call Summary
Plus Therapeutics Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.34M | 5.82M | 4.91M | 224.00K | 0.00 | 303.00K |
| Gross Profit | -616.00K | 4.97M | -4.78M | -488.00K | -66.00K | -2.40M |
| EBITDA | -18.95M | -8.40M | -12.69M | -18.85M | -12.05M | -6.76M |
| Net Income | -27.12M | -12.98M | -13.32M | -20.27M | -13.40M | -8.24M |
Balance Sheet | ||||||
| Total Assets | 12.06M | 6.63M | 11.39M | 23.87M | 21.98M | 12.11M |
| Cash, Cash Equivalents and Short-Term Investments | 9.87M | 3.61M | 8.55M | 18.12M | 18.40M | 8.35M |
| Total Debt | 40.00K | 3.37M | 4.18M | 5.64M | 6.99M | 7.00M |
| Total Liabilities | 35.70M | 15.58M | 12.74M | 17.42M | 11.14M | 9.07M |
| Stockholders Equity | -23.64M | -8.95M | -1.35M | 6.45M | 10.84M | 3.03M |
Cash Flow | ||||||
| Free Cash Flow | -12.87M | -10.70M | -13.01M | -13.48M | -10.42M | -8.93M |
| Operating Cash Flow | -12.21M | -10.55M | -12.85M | -12.97M | -10.28M | -8.43M |
| Investing Cash Flow | -189.00K | -4.11M | -160.00K | -759.00K | -82.00K | -493.00K |
| Financing Cash Flow | 19.37M | 6.19M | 3.44M | 13.45M | 20.42M | -319.00K |
Plus Therapeutics Technical Analysis
Plus Therapeutics Risk Analysis
Plus Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $52.45M | ― | -53.78% | ― | ― | -5.42% | |
| ― | $54.41M | -0.23 | -169.54% | ― | -100.00% | 29.21% | |
| ― | $54.89M | -0.43 | ― | ― | -5.77% | -22.78% | |
| ― | $53.75M | -0.24 | ― | ― | -3.49% | 27.88% | |
| ― | $44.82M | -0.27 | -93.85% | ― | -40.16% | 78.28% | |
| ― | $59.45M | ― | -47.87% | ― | ― | 18.86% |
Plus Therapeutics Corporate Events
Plus Therapeutics is advancing a pivotal study titled ‘Safety and Efficacy of Autologous Adipose-Derived Regenerative Cells (ADRCs) Injection for Improving Diminished Ovarian Reserve (ARISE)’. This study aims to assess the safety and efficacy of ADRCs injections in enhancing ovarian function in women with Diminished Ovarian Reserve (DOR), a condition that significantly impacts fertility. The study’s significance lies in its potential to offer a novel regenerative therapy for DOR, addressing a critical gap in current fertility treatments.
On October 16, 2025, Plus Therapeutics, Inc. entered into a lease agreement with LG 1 Property Owner LP for approximately 11,370 rentable square feet of space at 6420 Levit Green Boulevard, Houston, Texas. The lease, commencing on or about November 1, 2026, includes a monthly base rent of $58,745, with an annual increase of approximately 3%, and has an initial term of 120 months.
The most recent analyst rating on (PSTV) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Plus Therapeutics stock, see the PSTV Stock Forecast page.
On August 22, 2025, Plus Therapeutics, Inc. received confirmation from Nasdaq that it complies with Nasdaq Listing Rule 5550(b), meeting both the Market Value of Listing Securities standard and the alternative stockholders’ equity threshold. This compliance allows the company to extend its grace period to meet the $1.00 bid price rule until November 12, 2025. However, the company is subject to a one-year monitoring period regarding the Equity Standard. If it fails to maintain compliance within this period, Nasdaq will issue a delist determination letter, though the company can request a hearing to potentially stay further actions.
The most recent analyst rating on (PSTV) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Plus Therapeutics stock, see the PSTV Stock Forecast page.
Plus Therapeutics, Inc., based in Houston, Texas, is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system cancers, utilizing advanced platform technologies. The company recently reported its second-quarter financial results for 2025, highlighting significant progress in its clinical development and diagnostic platform initiatives. Key highlights include the launch timeline for the CNSide® CSF assay platform and the initiation of the REYOBIQ dose optimization trial for leptomeningeal metastases patients.
On June 3, 2025, Plus Therapeutics was notified by Nasdaq that it failed to meet the minimum stockholders’ equity requirement of $2.5 million, leading to a delist determination. However, after a hearing on July 15, 2025, the company was granted an extension to comply with the rule. By June 30, 2025, Plus Therapeutics reported stockholders’ equity of $3 million and continued to maintain compliance by selling over $2 million in common stock. The company also reported a market value of listed securities of at least $35 million for 20 consecutive business days as of August 13, 2025, meeting an alternative compliance threshold. Plus Therapeutics is awaiting Nasdaq’s confirmation of compliance with either the equity rule or the alternative market value requirement.
The most recent analyst rating on (PSTV) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Plus Therapeutics stock, see the PSTV Stock Forecast page.
On June 3, 2025, Plus Therapeutics was notified by the Nasdaq Listing Qualifications Department that it failed to meet the minimum stockholders’ equity requirement of $2.5 million, with a reported deficit of $23,641,000 as of March 31, 2025. Consequently, Nasdaq planned to delist the company’s securities unless an appeal was made. Following a hearing on July 15, 2025, the company was granted continued listing on July 22, 2025, provided it meets specific conditions by August 14, 2025, and September 8, 2025, including maintaining a minimum stock price and demonstrating compliance with equity requirements.
The most recent analyst rating on (PSTV) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Plus Therapeutics stock, see the PSTV Stock Forecast page.
On August 7, 2025, Plus Therapeutics held its Annual Meeting of Stockholders where five key proposals were voted on. The stockholders elected directors to the board, approved the potential issuance of up to $51 million in common stock to Lincoln Park Capital Fund, and granted the board authority for a reverse stock split. Additionally, the compensation of named executive officers and amendments to the 2020 Stock Incentive Plan were approved. These decisions reflect strategic moves to strengthen the company’s financial position and operational flexibility.
The most recent analyst rating on (PSTV) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Plus Therapeutics stock, see the PSTV Stock Forecast page.
Plus Therapeutics is conducting a Phase 1 clinical study titled ‘A Multicenter Phase 1 Study to Determine the Safety and Efficacy of Multiple Doses at Defined Intervals of Rhenium (186Re) Obisbemeda (Rhenium-186 NanoLiposome, 186RNL) Administered Via Intraventricular Catheter for Any Primary Solid Tumor Cancer With Leptomeningeal Metastases.’ The study aims to evaluate the safety and efficacy of multiple doses of 186RNL, a novel treatment for leptomeningeal metastases, a severe complication of cancer.